GT101
Phase 2Biologic
GT101 is one of 42 biologic programs targeting Cervical Cancer. It is currently in Phase 2.
1
Indications
3
Total Trials
3
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
380 competitors in Cervical Cancer
#DrugCompanyPhaseTrials
1Emend IV
Merck & Co.Phase 3
Hycamtin
MMeitheal
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Gemzar
Eli LillyPhase 3
Rescue
Merck & Co.Phase 3
Vindesine
GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
HLX10
Shanghai Henlius BiotechPhase 3
Neoadjuvant Therapy
SSun Yat-sen University
Phase 3
SG001
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Cervical Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GT101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- GGrit Biotechnology